1421373-07-0

Upstream product

• 603-76-9 1-methylindole 
• 120-72-9 indole 
• 59557-91-4 4-bromo-2-methoxyaniline 
• 1421373-08-1 N-(4-bromo-2-methoxy-5-nitrophenyl)-4-(1-methylindol-3-yl)pyrimidin-2-amine 
• 945016-63-7 3-(2-chloro-pyrimidin-4-yl)-1H-indole 
• 1032452-86-0 2-chloro-4-(1'-methyl-1H-indol-3-yl)pyrimidine 
• 1421371-97-2 4-bromo-2-methoxy-5-nitrobenzenamine 

Downstream Products

• 1421373-86-5 C₂₉H₃₀N₆O₂ 
• 1421373-06-9 4-methoxy-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N'-{4-(1-methylindol-3-yl)pyrimidine-2-yl}benzene-1,3-diamine 

Relevant academic research and scientific papers

EGFR tyrosine kinase of selective inhibitors of clinically significant mutant

Kinase can be prevented by the compound and the salt, especially epidermal growth factor receptor (EGFR,erbB-2,erbB-4) and kinase clinica important gatekeeper 'mutant'; and abnormal cell profilerative diseases such as cancers can be treated or improved.

2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER

The present invention relates to certain 2-(2,4,5-substituted-anilino) pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.